{"disease":{"id":"treatment-of-chronic-sinusitis","name":"treatment of chronic sinusitis"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of chronic rhinosinusitis with and without nasal polyps","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}